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Purpose of the study
First line HAART with tenofovir DF (TDF) and emtrici-
tabine (FTC) in pivotal trials has been associated with
high efficacy and good tolerability. However, real-life
clinical practice often differs from clinical trials due to
co-morbidities, co-infections, and less intensive clinical
monitoring.
Methods
Between July 2005 and August 2006, 534 HIV
+ antire-
troviral naïve patients (pts) from 50 German centres
enrolled in this non-interventional cohort. All patients
were to be followed for three years every three months
to monitor and document efficacy (VL, CD4), renal
safety, tolerability, regimen changes and resistance pro-
file. All patients received TDF+FTC as a single tablet
fixed-combination (Truvada, TVD) mostly in combina-
tion with either NNRTI or PI/r as their first regimen.
Summary of results
As of April 2010, three years of therapy have been docu-
mented for 330/534 (61.8%) pts; 81% male; median age
was 39 years. Clinical AIDS diagnosis was documented in
22% pts; 46% pts started therapy with median 211 (IQR:
111-297) CD4 cells/mm
3. TVD was combined with
NNRTI (efavirenz (EFV)27%, nevirapine 16%), PI/r (54%)
or other (3%). In an as treated analysis after 36 months,
91% of pts achieved VL<50 copies/mL (VL<200 copies/
mL: 97.1%; VL<500 copies/ml: 99%). Median CD4 cell
count increased to 472 cells/mm
3 (IQR: 341-631). Regi-
men with TVD showed a good safety profile and 36 pts
were switched to a single tablet regimen with EFV/TDF/
FTC (Atripla); 113 adverse events (AEs) of any grade were
reported in 73/534 pts (13.7%); 15 of these were rated ser-
ious. 21 (3.9%) pts discontinued the TVD regimen due to
AEs. Most of them (n=13) discontinued within the first six
months. Renal abnormalities of any grade were reported
in 10 pts (8.8% of all AEs). Median creatinine clearance
was 109.0 mL/min (n=444) at baseline and 103.3 mL/min
(n=287) after 36 months. Virological failure as a reason for
discontinuation was documented in 12 pts; in 11 failing
pts genotyping was performed and detected M184V (n=2)
or K65R (n=2) among other NRTI, PI or NNRTI muta-
tions. One failing patient had shown M184V at baseline.
Conclusions
During three years of follow-up, overall safety of TVD
was good. Virological failure was rare (12 pts) and K65R
was detected in only 2 failing patients. First line
HAART with Truvada (TDF/FTC) plus an NNRTI or
PI/r in clinical practice showed comparable efficacy to
that observed in controlled clinical trials.
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